Todas las noticias

• Annual revenue of €12 million (+14%) • Operating income close to breakeven • Reduction in net loss

Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce que la Cour d’appel du Deleware (United States Court of Appeals for the third circuit) a décidé, dans un jugement rendu le 19 mars 2025, de confirmer la décision rendue en première instance et déboutant le groupe Spineway de sa demande d’exécution de la sentence arbitrale rendue à Genève qui faisait droit à la demande au fond de Spineway.

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, took part in the 2025 edition of the Arab Health trade fair, which was held at the Dubai World Trade Centre from January 27 to 30, 2025. This unmissable event for the medical sector in the Middle East offered Spineway the chance to strengthen its presence in the region and expand its distribution network.

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, is reporting annual revenue of €11.9 million in FY 2024, representing organic growth of 14% (excluding changes in the scope of consolidation) compared with FY 2023. This acceleration benefited from the successful integration of the Distimp and Spine Innovations acquisitions, which have strengthened the Group’s premium ranges and boosted sales in this segment.

El Grupo Spineway, especialista en implantes innovadores para el tratamiento de trastornos graves de la columna vertebral, celebró el jueves 5 de diciembre un seminario web en el que Stéphane Le Roux, Director General de Spineway, repasó los últimos avances del Grupo y confirmó su hoja de ruta para los próximos años.

El Grupo Spineway, especialista en implantes innovadores para el tratamiento de trastornos graves de la columna vertebral, celebró el jueves 5 de diciembre un seminario web en el que Stéphane Le Roux, Director General de Spineway, repasó los últimos avances del Grupo y confirmó su hoja de ruta para los próximos años.

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces that the Board of Directors of Spineway (the “Company”) decided at its meeting of December 4, 2024, acting on a delegation of authority granted by the Combined General Meeting of March 25, 2024, under the terms of its twenty-third resolution, to carry out a capital reduction motivated by losses through a reduction in the par value of its shares.

The Spineway Group, a , specialist in innovative implants for the treatment of severe spine disorders, organized a week of training dedicated to medical education from November 4 to 8, 2024. Through practical sessions in the operating room and on anatomical specimens in the laboratory, this intensive program trained over 20 international surgeons in the use of the Group’s ESP cervical and lumbar prostheses. These events also enabled the Group's distributors to provide ongoing training and support for their users.

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, took part in the EUROSPINE 2024 Congress, Europe’s leading spine conference, held from October 2 to 4, in Vienna, Austria. During the event, which brought together more than 3,500 spine surgeons and professionals from all over the world, Spineway enjoyed a prime location in the heart of the Messe Wien congress center, making its stand a must see for all congress attendees.